Oncology 2019, Sept 26-27, Paris, France
Events Past EventsABOUT THE ONCOLOGY 2019 Fearless commitment for a Cancer free world Hilaris Conferences warmly invite you to meet inspiring speakers and experts for the conference Oncology 2019 in Paris, FranceRead more(ESMO) European Society for Medical Oncology Congress 2019, Sept 27-Oct 1, Barcelona Spain
Events Past EventsThe ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latestRead moreImmunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. as VP, Clinical Development
Featured Press Press ReleasesJuly 12, 2019 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. asRead moreImmunomic Therapeutics Announces Promotion of Teri Heiland, Ph.D. to Chief Scientific Officer
Featured Press Press ReleasesJune 20, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer.Read moreImmunomic Therapeutics to Present at China Focus @BIO Philadelphia
Press ReleasesMay 30, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the ChinaRead moreSachs’ 5th Annual Immuno-Oncology BD&L and Investment Forum
Events Past EventsABOUT THE 5TH ANNUAL IMMUNO-ONCOLOGY FORUM Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patientRead moreImmunomic Therapeutics to Participate at Sachs’ 5th Annual Immuno-Oncology BD&L and Investment Forum
Press ReleasesMay 24, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 5th Annual Immuno-oncologyRead moreImmunomic Therapeutics to Participate at World Vaccine Congress Washington 2019
Press Press ReleasesApril 04, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate at the World Vaccine Congress Washington being held in Washington, D.C.Read moreImmunomic Therapeutics Presents Late-Breaking Preclinical Data on DNA Vaccine ITI-7000 at AACR 2019
BlogImmunomic Therapeutics, Inc. today presented late-breaking preclinical data which shows that its investigational nucleic acid platform, UNITE, may enhance antitumor immunity when used in connection with its investigational DNA vaccine,Read moreWorld Vaccine and Immunotherapy West Coast, December 3-5, 2019, San Francisco, CA
Events Past EventsITI will be sponsoring the World Vaccine and Immunotherapy Congress for the second year in a row. After an incredibly successful two years in San Diego, the World Vaccine andRead more34th Annual Meeting & Pre-Conference Programs (SITC 2019), November 6-10, Washington, DC
Events Past EventsThe Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the worldRead more